You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients
|
|---|---|
| Published in |
Cardiovascular Diabetology, February 2017
|
| DOI | 10.1186/s12933-017-0509-7 |
| Pubmed ID | |
| Authors |
Aurélien Mary, Agnes Hartemann, Sophie Liabeuf, Carole Elodie Aubert, Salim Kemel, Joe Elie Salem, Philippe Cluzel, Aurélie Lenglet, Ziad A. Massy, Jean-Daniel Lalau, Romuald Mentaverri, Olivier Bourron, Saïd Kamel |
| Abstract |
Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, metformin's effects in patients with diabetic VC have not previously been characterized. The present study investigated the association between metformin use and lower-limb arterial calcification in patients with type 2 diabetes and high cardiovascular risk. The DIACART cross-sectional cohort study included 198 patients with type 2 diabetes but without severe chronic kidney disease. Below-the-knee calcification scores were assessed by computed tomography and supplemented by colour duplex ultrasonography. Data on anti-diabetic drugs were carefully collected from the patients' medical records and during patient interviews. Biochemical and clinical data were studied as potential confounding factors. Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0.01). A univariate analysis showed that metformin was associated with a significantly lower prevalence of severe below-the-knee arterial calcification (p = 0.02). VC was not significantly associated with the use of other antidiabetic drugs, including sulfonylureas, insulin, gliptin, and glucagon like peptide-1 analogues. A multivariate logistic regression analysis indicated that the association between metformin use and calcification score (odds ratio [95% confidence interval] = 0.33 [0.11-0.98]; p = 0.045) was independent of age, gender, tobacco use, renal function, previous cardiovascular disease, diabetes duration, neuropathy, retinopathy, HbA1c levels, and inflammation. In patients with type 2 diabetes, metformin use was independently associated with a lower below-the-knee arterial calcification score. This association may contribute to metformin's well-known vascular protective effect. Further prospective investigations of metformin's potential ability to inhibit VC in patients with and without type 2 diabetes are now needed to confirm these results. |
X Demographics
The data shown below were collected from the profiles of 27 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 8 | 30% |
| United States | 3 | 11% |
| France | 3 | 11% |
| Spain | 1 | 4% |
| Australia | 1 | 4% |
| South Africa | 1 | 4% |
| Unknown | 10 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 78% |
| Practitioners (doctors, other healthcare professionals) | 3 | 11% |
| Science communicators (journalists, bloggers, editors) | 2 | 7% |
| Scientists | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Qatar | 1 | 1% |
| Unknown | 84 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 14% |
| Student > Bachelor | 12 | 14% |
| Other | 9 | 11% |
| Researcher | 9 | 11% |
| Student > Doctoral Student | 5 | 6% |
| Other | 16 | 19% |
| Unknown | 22 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 40% |
| Nursing and Health Professions | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Psychology | 3 | 4% |
| Other | 8 | 9% |
| Unknown | 27 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2022.
All research outputs
#2,131,113
of 23,576,969 outputs
Outputs from Cardiovascular Diabetology
#137
of 1,467 outputs
Outputs of similar age
#51,103
of 457,009 outputs
Outputs of similar age from Cardiovascular Diabetology
#4
of 28 outputs
Altmetric has tracked 23,576,969 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,467 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 457,009 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.